Austin Indian Community - AustinIndian.com
| | | | | | | | | | | |
 


 

Dr Reddy's ties up with Fujifilm, GRA for potential Covid drug

Andhra Pradesh,National,Health/Medicine

Author : Indo Asian News Service

Health/Medicine, National, Andhra Pradesh, India Read Latest News and Articles

Share With Your Friends



Add an Article

View All Contributions

Add To My Favorite

Add A Picture

Hyderabad, July 1 (IANS) Pharma major Dr Reddy's Laboratories Ltd on Wednesday announced that it has partnered with Fujifilm Corporation, through Fujifilm Toyama Chemical Co Ltd, and Global Response Aid (GRA) for the development, manufacture and sales of Avigan tablets (generic name favipiravir), a potential treatment for Covid-19.

Under the tripartite agreement, Fujifilm has granted Dr Reddy's the exclusive rights of manufacturing and also granted both Dr Reddy's and GRA the rights to develop, sell and distribute Avigan in all countries other than Japan, China and Russia.

Dr Reddy's would have exclusive rights for development, selling and distribution of Avigan in India. Further, Fujifilm would receive an upfront license fee and royalties on sales from Dr Reddy's and GRA, Hyderabad-based Dr Reddy's said in a statement.

Fujifilm will provide Dr Reddy's and GRA with an array of data on Avigan's pre-clinical and clinical studies that Fujifilm has accumulated thus far. Dr Reddy's and GRA will use this data for clinical studies targeting Covid-19 in regions where infection has been spreading.

Fujifilm will also grant Dr Reddy's right to use Avigan's patents of formulation and manufacturing method. Dr Reddy's will establish a setup for manufacturing drugs of the same quality as Avigan and utilise GRA's global sales network to supply the manufactured drugs swiftly and in a stable manner.

The Fujifilm Group is currently conducting a clinical study on Avigan targeting Covid-19 patients in Japan and the US, and is working to increase the drug's production by partnering with domestic and overseas companies. Dr Reddy's and GRA shall introduce the product in the market post all applicable approvals in the respective countries.

--IANS

ms/vd


Copyright and Disclaimer: All news and images appearing in our news section, search engines and social media are provided by IANS. If you face any issues related to the content/images, please contact our news service provider directly. We are not liable/responsible for any content/images related to the news service provider.


Latest News

View More News


More News Articles

IPL 2024: All it needs is to win a couple of games and you are back in contention, says Rashid Khan

IPL 2024: All it needs is to win a couple of games and you are back in contention, says Rashid Khan

Aditi Rao Hydari's b'day wish for 'manicorn' Siddharth: 'Endless laughter, happiness'

Aditi Rao Hydari's b'day wish for 'manicorn' Siddharth: 'Endless laughter, happiness'

Why Vidya Malvade says she felt she would become 6 feet tall by end of 'Ruslaan' shoot